North America Atopic Dermatitis Market Research, 2032
The North America atopic dermatitis market size was valued at $2,601.44 million in 2022 and is projected to reach $10,748.48 million by 2032, registering a CAGR of 14.8% from 2023 to 2032.
The growth of the North America atopic dermatitis market is driven by the surge in the prevalence of atopic dermatitis and rise in demand for effective treatment. According to a 2022 report by the National Eczema Association, an estimated 31.6 million people (10.1%) in the U.S. have some form of eczema, and prevalence peaks during early childhood.
Key Takeaways:
- By drug class, the biologics segment was the highest contributor to the market in 2022.
- By mode of administration, the injectable segment was the highest contributor to the market in 2022.
- By distribution channel, the hospital pharmacies segment dominated the market in 2022, and is expected to remain dominant during the forecast period.
Atopic dermatitis is a condition that causes skin to become dry, red, itchy and bumpy. It is one of many types of dermatitis. It damages the skin barrier function. This loss of barrier function makes the skin more sensitive and more prone to infection and dryness. Atopic dermatitis does not harm the body. It does not mean that the skin is dirty or infected, and it is not contagious. There are treatments that can help manage the symptoms. In the word “dermatitis,” “derm” means “skin” and “itis” means “inflammation.” The word as a whole means “inflammation of the skin.” “Atopic dermatitis” originates from the Greek word “ekzein” which means to “boil over” or “break out.
Market dynamics
The North America atopic dermatitis market share is expected to grow significantly, owing to surge in prevalence of atopic dermatitis, rapid development of novel pipeline drugs, and high preference towards the automated microscope by the researchers. Furthermore, rise in demand for new biologics and product approvals, and increase in number of atopic dermatitis industry are predicted to enhance the atopic dermatitis market growth. Furthermore, the favorable reimbursement policies in emerging countries and high prevalence of atopic dermatitis are also projected to drive the market growth rate.
The increase in awareness regarding the availability of treatments for the disease and various initiatives undertaken by governments to provide better and more affordable treatment are also expected to influence the atopic dermatitis market share globally. In addition, the rapid technological advancement and the rise in funding along with increase in government support for research and development are likely to create various new opportunities that will impact the atopic dermatitis market growth during the forecast period.
Atopic dermatitis does not affect critical markets regularity in patients hospitalized with coronavirus. Adults with atopic diseases are at significant risk of lower respiratory tract infections (LRTIs) and upper respiratory tract infections (URTIs) than those without atopic diseases. Patients infected with corona virus did not face any difficulties during their infection course. Moreover, patients with atopic dermatitis are said to have efficient and safe therapy with dupilumab. All these factors are expected to accelerate the growth rate of the global atopic dermatitis market.
However, the easy availability of expensive treatment and poor reimbursement policies in the developing regions across the globe are expected to act as major restraints toward the growth of the atopic dermatitis market, whereas the allergic reactions of off-label therapies and patent expiry of products can restrict the growth of the atopic dermatitis market during the forecast period.
Segmental Overview
The North America atopic dermatitis market analysis is segmented on the basis of drug class, mode of administration and distribution channel. Depending on drug class, the market is classified into corticosteroids, calcineurin inhibitors, PDE4 inhibitors, biologics, and others. By mode of administration, the market is classified into topical, injectable, and oral. According to distribution channel, the North America atopic dermatitis market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
By Drug class:
The North America atopic dermatitis treatment market is categorized into corticosteroids, calcineurin inhibitors, PDE4 inhibitors, biologics, and others. The biologics segment dominated the global atopic dermatitis treatment market in 2022 and is anticipated to continue this trend during the forecast period. This is attributed to an increase in awareness regarding the availability of treatments for the disease and rise in various initiatives undertaken by governments to provide better and more affordable treatment. Moreover, new product launches and increased adoption of biological drugs across several regions are the factors propelling the segment growth.
By Drug Class
Biologics segment held a dominant position in the market in 2022 and Corticosteroids is anticipated to grow at the fastest rate during the forecast period.
By Mode of Administration:
By mode of administration, the market is categorized into topical, injectable, and oral. The injectable segment dominated the global market in 2022 and is anticipated to remain dominant during the forecast period due to an increase in product approvals of drugs. Doctors have also started prescribing corticosteroids via injections for faster effects on patients.
By Distribution Channel:
On the basis of distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2022, owing to high prevalence of atopic dermatitis, rise in prices of drugs, increase in income levels of poor & middle-class families, and approval of drugs. Moreover, surge in number of initiatives from various governmental bodies in improving the infrastructure of hospitals and pharmacies is expected to foster the growth of the hospital pharmacies segment.
Competition Analysis
Some of the major companies that operate in the North America atopic dermatitis market, include AbbVie Inc., Arcutis Biotherapeutics, Inc, Asana Biosciences, Inc, Dermavant Sciences, Inc., Pfizer Inc., Bayer AG, Novartis AG, Eli Lilly and Company, Sanofi and Viatris Inc. Major players have adopted product launch as key developmental strategy to improve their product portfolio and gain strong foothold in the North America atopic dermatitis market trends.
Recent product approval in the North America Atopic Dermatitis Market
In February 2021, Asana pharmaceutical received the approval for Asana’s gusacitinib (ASN002), for the treatment of moderate-to-severe chronic hand eczema (CHE).
In May 2022, Dermavant sciences received the approval for Dermavant’s VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults.
In June 2022, Sanofi SA, a global pharmaceutical company received the Food and Drug Administration (FDA) approval for its first biologic drug Dupixent for the treatment of moderate-to-severe atopic dermatitis in adults.
North America Atopic Dermatitis Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Mode of Administration |
|
 By Distribution Channel |
|
 By Country |
|
 Key Market Players | Eli Lilly and Company, Sanofi, Bayer AG, Pfizer Inc., Novartis AG, Dermavant Sciences, Inc.,, Viatris Inc., Arcutis Biotherapeutics, Inc, Asana Biosciences, Inc, AbbVie Inc |
Analyst Review
Atopic dermatitis, also known as eczema, is a condition associated with dry, itchy, and inflammatory skin. It can occur at any age, although it is more prevalent in young children. The increase in the prevalence of atopic dermatitis, and surge in awareness about skin disorders drive the market growth. The atopic dermatitis market is expected to witness increased adoption of advanced therapy in the near future, owing to rise in the number of immunization programs across the globe.
In addition, the strategies such as acquisition and merger adopted by key players contribute to the growth of the market. Furthermore, the adoption of increase in treatment options for all age groups and severities is propelling the growth of the market. Also, some of the new JAK inhibitors are topical therapies that address key needs in the mild-to moderate patient segment, with hopes that the inhibitors will not have any side effect of topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs).
The total market value of the North America Atopic Dermatitis Market is $2,601.44 million in 2022.
The forecast period in the report is from 2023 to 2032
There are 10 North America Atopic Dermatitis manufacturing companies are profiled in the report
The base year for the report is 2022.
Yes, North America Atopic Dermatitis companies are profiled in the report
The top companies that hold the market share in AbbVie Inc., Arcutis Biotherapeutics, Inc, Asana Biosciences, Inc, Dermavant Sciences, Inc., and Pfizer Inc.
Yes, the competitive landscape included in the North America Atopic Dermatitis Market report
U.S. is the largest country market for North America Atopic Dermatitis
Loading Table Of Content...
